Bausch + Lomb launches $1.4B notes offering and $500M term loan for XIIDRA acquisition

Bausch Health Companies Inc.

Bausch + Lomb Escrow Corp. launched $1.4B senior secured notes due 2028; Bausch + Lomb seeks $500M incremental term B loan.
Net proceeds to fund XIIDRA acquisition, fees, expenses, and general corporate purposes including debt repayment.
Notes offering not conditioned on acquisition close; if not closed by Sept 30, 2024, notes redeemed at par plus accrued interest.
Preliminary purchase price allocation adjustments: prepaid assets reduced $22M, non-current liabilities reduced $12M, goodwill increased $10M.
Adjustments reduced amortization expense by $43M for FY2022 and $20M for six months ended June 2023; no impact on revenue or Adj. EBITDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.